Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements.
Marta MattanaRiccardo TomaselloClaudia CammarataPaola Di CarloTeresa FascianaGiulio GiordanoAlessandro LucchesiSergio SiragusaMariasanta NapolitanoPublished in: Microorganisms (2022)
C. difficile enterocolitis (CDAC) is the most common hospital infection, burdened by an increased incidence of coagulation-related complications such as deep vein thrombosis (DVT) and disseminated intravascular coagulation (DIC) as well as a significant sepsis-related mortality. In this review, we analyzed the available data concerning the correlation between coagulation complications related to C. difficile infection (CDI) and inflammasome activation, in particular the pyrin-dependent one. The little but solid available preclinical and clinical evidence shows that inflammasome activation increases the risk of venous thromboembolism (VTE). As proof of this, it has been observed that in vitro inhibition of the molecules (e.g., tissue factor) mainly involved in coagulation activation could block the process. In vivo studies show that it could be possible to reduce the incidence of complications associated with C. difficile infection (CDI) and mortality due to a state of hypercoagulability. A personalized therapeutic approach to reduce the inflammatory activity and prevent thromboembolic complications could be preliminarily defined to reduce mortality.
Keyphrases
- risk factors
- clostridium difficile
- venous thromboembolism
- cardiovascular events
- intensive care unit
- healthcare
- coronary artery
- acute kidney injury
- oxidative stress
- emergency department
- coronary artery disease
- stem cells
- atrial fibrillation
- direct oral anticoagulants
- mesenchymal stem cells
- electronic health record
- cell therapy
- high glucose
- endothelial cells
- septic shock
- case control